Acute coronary syndrome is infrequent, presents most often as non-STEMI, but is associated with high early mortality.
Although as many as 50% of patients who undergo transcatheter aortic-valve replacement (TAVR) have known coronary artery disease, the incidence of acute coronary syndrome (ACS) after TAVR is unknown.
Código de aprobación:PP-CVP-PEB-0048
Portal web de Pfizer para Profesionales, donde podrá acceder a una amplia variedad de contenidos y servicios tales como:
Confirmo que soy profesional de la salud residente en Perú.
Si no es profesional de la salud consulte
www.pfizer.com.pe